TABLE 1.
Baseline characteristics for the IGNITE study cohort
| Patients with a prescription for oral semaglutide | |
|---|---|
| Demographic characteristics (N = 782) | |
| Age at index date, mean (SD) | 57.8 (11.3) |
| Sex (men/women), % | 45.5/54.5 |
| Race, n (%) | |
| African American | 181 (23.1) |
| Asian | 21 (2.7) |
| Caucasian | 558 (71.4) |
| Other/unknown | 22 (2.8) |
| Region, n (%) | |
| Midwest | 503 (64.3) |
| South | 274 (35.0) |
| Other | 5 (0.6) |
| Provider speciality, n (%) | |
| Endocrinology | 135 (17.3) |
| Primary care practitioner | 516 (66.0) |
| Other/unknown | 131 (16.8) |
| Clinical characteristics a (baseline period: 3 mo) | |
| Weight, kg (N = 689) | 104.9 (24.0) |
| BMI (N = 687) | |
| Mean (SD), kg/m2 | 36.2 (7.6) |
| <30 kg/m2, n (%) | 154 (22.4) |
| 30‐<35 kg/m2, n (%) | 186 (27.1) |
| ≥35 kg/m2, n (%) | 347 (50.5) |
| HbA1c (N = 499) | |
| Mean (SD), % | 8.4 (1.8) |
| ≤7%, n (%) | 112 (22.4) |
| 7‐<10%, n (%) | 303 (60.7) |
| ≥10%, n (%) | 84 (16.8) |
| <8%, n (%) | 236 (47.3) |
| ≥8%, n (%) | 263 (52.7) |
| <9%, n (%) | 356 (71.3) |
| ≥9%, n (%) | 143 (28.7) |
| LDL cholesterol level (N = 297) | 91.4 (43.8) |
| ≥70 mg/dL, n (%) | 204 (68.7) |
| Time with T2D in the databaseb, years (N = 782) | 6.9 (4.8) |
| Co‐morbidities (N = 782; baseline period: 12 mo) | |
| Charlson co‐morbidity index scorea, mean (SD) | 2.43 (2.11) |
| Number of co‐morbidities, mean (SD) | 2.3 (1.5) |
| Any microvascular condition, n (%) | 232 (29.7) |
| Diabetic retinopathy, n (%) | 47 (6.0) |
| Diabetic neuropathy, n (%) | 150 (19.2) |
| Diabetic nephropathy, n (%) | 98 (12.5) |
| Established CVDc, n (%) | 224 (28.6) |
| Hypertension, n (%) | 573 (73.3) |
| Stroke, n (%) | 45 (5.8) |
| Acute MI, n (%) | 30 (3.8) |
| Antidiabetic medications (N = 782; baseline period: 12 mo) | |
| Number of glucose‐lowering agents | 2.1 (1.7) |
| No antidiabetic medications | 156 (19.9) |
| Baseline medication, n (%) | |
| Biguanides | 456 (58.3) |
| Sulphonylureas | 232 (29.7) |
| Thiazolidinediones | 61 (7.8) |
| DPP‐4is | 152 (19.4) |
| SGLT‐2is | 199 (25.4) |
| Any GLP‐1 RA | 179 (22.9) |
| Dulaglutide | 80 (10.2) |
| Liraglutide | 64 (8.2) |
| Injectable semaglutide | 48 (6.1) |
| Exenatide | 18 (2.3) |
| Lixisenatide | 6 (0.8) |
| Any insulin | 190 (24.3) |
| Long‐acting insulin | 168 (21.5) |
| Fast‐acting insulin | 114 (14.6) |
| Oral semaglutide dosing (N = 782) | |
| Initial oral semaglutide dose, n (%) | |
| 3 mg | 404 (51.7) |
| 3 and 7 mg | 112 (14.3) |
| 3, 7 and 14 mg | 5 (0.6) |
| 7 mg | 201 (25.7) |
| 7 and 14 mg | 8 (1.0) |
| 14 mg | 41 (5.2) |
| Unknown | 11 (1.4) |
| Highest oral semaglutide dose, n (%) | |
| 3 mg | 289 (37.0) |
| 7 mg | 379 (48.5) |
| 14 mg | 106 (13.6) |
Note: Data are mean (SD) except where otherwise stated.
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; LDL, low‐density lipoprotein; MI, myocardial infarction; SD, standard deviation; SGLT‐2i, sodium‐glucose co‐transporter‐2 inhibitor; T2D, type 2 diabetes.
Last measurement or score available before index date.
Time with T2D in the database was the closest approximation of disease duration available from a data source such as this.
Included conditions were ischaemic heart disease, pulmonary embolism, transient cerebral ischaemic attacks and related syndromes, presence of cardiac and vascular implants and grafts, cardiomyopathy, cardiac arrest, atrial fibrillation, cardiac arrhythmia, heart failure, cerebrovascular disease, atherosclerosis, peripheral vascular disease, embolism and thrombosis.